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Oxidative stress (OS) and production of NO, by endothelium nitric oxide synthetase (eNOS), are involved in the pathophysiology
of erectile dysfunction (ED). Moreover, OS induces modifications of the physicochemical properties of erythrocyte (RBC) plasma
membranes and of the enzyme content of the same membranes. Due to their role in signalling early membrane alterations in OS-
related pathologies, several plasmamembrane and cytosolic glycohydrolases of human RBC have been proposed as newmarkers of
cellularOS. In RBC,NOS can be activated and deactivated by phosphorylation/glycosylation. In this regulatorymechanismO-𝛽-N-
AcetylGlucosaminidase is a key enzyme. Cellular levels of O-GlcNAcylated proteins are related to OS; consequently dysfunctional
eNOS O-GlcNAcylation seems to have a crucial role in ED. To elucidate the possible association between RBC glycohydrolases
and OS, plasma hydroperoxides and antioxidant total defenses (Lag-time), cytosolic O-𝛽-N-AcetylGlucosaminidase, cytosolic and
membrane Hexosaminidase, membrane 𝛽-D-Glucuronidase, and 𝛼-D-Glucosidase have been studied in 39 ED patients and 30
controls. In ED subjects hydroperoxides and plasma membrane glycohydrolases activities are significantly increased whereas Lag-
time values and cytosolic glycohydrolases activities are significantly decreased. These data confirm the strong OS status in ED
patients, the role of the studied glycohydrolases as early OS biomarker and suggest their possible use as specific marker of ED
patients, particularly in those undergoing nutritional/pharmacological antioxidant therapy.
1. Introduction
Erectile dysfunction (ED) [1] is defined as the inability to
achieve or maintain erection of the penis during sexual
intercourse. Although ED is amultifactorial process, vascular
disease of the penile arteries is an important cause in up to
80% of cases [2]. Penile erection results from the interaction
of different physiologic systems involving the central and
peripheral nervous system and endothelial and vascular
smooth muscle cells of the corpora cavernosa [3]. There is
growing interest among researchers in the role of oxidative
stress (OS) in the pathophysiological mechanism of ED [4].
The impairment of penile vascular function is associated
with erectile dysfunction in a variety of vascular disorders
characterized by a strong oxidative stress, including diabetes
mellitus [5]. OS is the direct consequence of imbalance
between the production of reactive oxygen/reactive nitro-
gen species (ROS and RNS) and intracellular antioxidant
defenses.
It is well known that OS leads to alterations of physico-
chemical properties and enzyme activities [6] of erythrocyte
plasma membrane.
Glycohydrolases catalyse the hydrolysis of specific glyco-
sidic linkages in naturally occurring glycosides or glycocon-
jugates. They are ubiquitously distributed, mainly located
in lysosomes, and have been found in other intracellu-lar
vesicles with acidic matrix, in plasma membranes, cyto-
sol, and blood plasma [7, 8]. Plasma membrane and
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cytosol glycohydrolases, namely, Hexosaminidase (HEX), 𝛽-
D-Glucuronidase (GCR), 𝛼-D-Glucosidase (𝛼-GLU), and
O-𝛽-N-Acetyl-glucosaminidase (O-GlcNAcase,), were also
found in human erythrocytes where [9, 10] they have a role
in signalling early membrane alterations [6], in pathologies
related to strong oxidative stress, such as type 2 diabetes
mellitus [11] or Down’s syndrome [12, 13]. For these reasons
their use as new markers of cellular oxidative stress has been
suggested [6, 13, 14].
In particular, O-GlcNAcase is a nuclear-cytoplasmic
enzyme, recently found also in erythrocyte plasma mem-
brane [10], cloned and characterized for the first time byDong
and Hart [15]. Together with O-GlcNAc transferase (OGT),
O-GlcNAc ase plays a key role in the dynamic process of
the O-linked 𝛽-N-acetylglucosamine (O-GlcNAc) proteins
[16]. A large group of cytosolic and nuclear proteins carry
single residues of O-linked GlcNAc and undergo functional
modification after insertion or detachment of GlcNAc [17]. In
such contest, O-GlcNAcase has a crucial role in the regulation
of NO production (NO is, probably, the principal neuromod-
ulator of penile erection [18]) acting in the regulatory cycle
of O-glycosylation/phosphorylation of the specific residue
of Ser 1177 in the active site of endothelium nitric oxide
synthetase (eNOS).
A recent study has shown that in human erythrocytes
(RBC) a NOS (RBC-NOS) is present which, like eNOS,
can be phosphorylated/glycosylated at the same specific site
[19] and that its activation is induced by fluid shear stress
stimuli and vascular endothelium growth factor signalling.
Consequently, and considering the role of RBC-NOS in NO
production [20] and the recently proposed role of RBC-NOS
in releasing NO during shear stress [21, 22], it is possible
to hypothesize that also RBC-NOS could have a role in
cavernous smooth muscle relaxation. Furthermore, recent
studies show an impairment of NO pathway in RBC associ-
ated with a decrease of NO synthase activity in pathologies
related to strong oxidative stress as, for example, coronary
artery disease [23, 24].
Therefore we measured the above-mentioned enzyme
activities both in membrane and cytosol of erythrocytes of
ED patients to evaluate their possible involvement in ED and
their possible use to mark oxidative stress and to monitor the
patients that undergo antioxidant treatment [25].
2. Materials and Methods
2.1. Subjects. 39 ED patients, aged 52.9 ± 10.6, were recruited
from U.O. Andrology of San Paolo University Hospital, Milan,
Italy. Controls were 30 adult male volunteer blood donors,
aged 50.1 ± 5.9, from the Italian association of blood volun-
teers (AVIS) in Milan, Italy. This investigation conforms to
the principles outlined in the Declaration of Helsinki. Signed
informed written consent was obtained from all subjects
before their participation in the study. No ethics approval
was required because no additional blood was needed for this
study and this was explained thoroughly to all patients. This
procedure has been accepted by several journals [26].
Erectile function was assessed on an appropriate clinical
work-up study and by using the abridged five-item version
of the International Index of Erectile Function questionnaire
(IIEF-5), a validated, self-administered questionnaire [27];
all subjects were classified with erectile dysfunction (IIEF =
13 ± 5). All subjects were selected based on the following
exclusion criteria: coronary artery disease, diabetes mellitus,
hypertension, malignancy, renal failure, congestive heart
failure, systemic inflammatory disease, or heart arrhythmias.
2.2. Materials. Commercial chemicals were of the highest
available grade. The water routinely used was freshly redis-
tilled in a glass apparatus. Bovine serum albumin (BSA),
CuSO
4
, 1,6-Diphenyl-1,3,5-hexatriene (DPH), its cationic
derivative 1-[4-(trimethyl-amino)-phenyl]-6-phenyl-1,3,5-
hexatriene (TMA-DPH), 4-Methylumbelliferone (MUB), 𝛼-
and 𝛽-glycosides, used as enzyme substrates, and N-Acetyl-
D-galactosamine (GalNAc) were purchased from Sigma
Chemical Co. (St. Louis, MO,USA). MUB, purchased from
Fluka GmbH (Buchs, Switzerland), was recrystallized from
ethanol three times.
d-ROMs kit test was purchased from Diacron Interna-
tional (Grosseto, Italy).
2.3. Blood Sampling and Preparation of Erythrocyte Mem-
brane and Cytosolic Fractions. Erythrocytes and plasma were
prepared from heparinized venous blood. In brief, after
collection, the blood samples were immediately centrifuged
for 15min at 3000×g and plasma immediately withdrawn
and stored at −20∘C until further assays. The buffy coat,
aspirated from the surface of the pellet, was discarded and the
residual material was diluted (1 : 1, v/v) with phosphate buffer
solution (PBS) at pH 7.4 and filtered with Leucostop 4LT-
B filters (Baxter Spa, Mirandola, Modena, Italy) in order to
remove all platelet and leukocyte contaminants. The filtered
material, containing only erythrocytes, was centrifuged for
5min at 1200×g and the pellet was washed twice (1200×g per
5min) with PBS at pH 7.4 and immediately used for ghost
preparation. Unsealed ghost membranes were prepared at
4∘C according to the method of Steck and Kant [28], which
employs hypotonic treatment (from 5.0 to 1.25mmol/L PBS,
pH 8.0). Cytosol was obtained by pooling the three super-
natants from the hypotonic treatments for the preparation of
unsealed ghost membranes.
2.4. Enzyme Assays. The following glycohydrolases were
assayed with a microfluorimetric method utilizing 4-MU-
glycosides as substrates and following the methods of Goi
et al. [9]: O-GlcNAcase (E.C. 3.2.1.169), HEX (E.C. 3.2.1.52),
GCR (E.C. 3.2.1.31), and 𝛼-GLU (E.C. 3.2.1.20). Briefly, 50 𝜇L
of erythrocytes plasma membrane or cytosolic fractions,
diluted as necessary, was incubated in a final volumeof 250𝜇L
containing 25 𝜇L of 50mmol/L citric acid-sodium phosphate
buffer at appropriate pH, and 175 𝜇L of the specific substrate
dissolved in water. The mixtures were incubated in a shaker
bath at 37∘C for the established period of time. The reaction
was stopped and fluorescence developed by adding 750𝜇L of
alkaline solution (0.2mol/L glycine-NaOH buffer, containing
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Table 1: Clinical and metabolic parameters of controls and ED patients.
Controls
𝑁 = 30
ED patients
𝑁 = 39
Reference ranges
Age, years 50.1 ± 16.6 52.9 ± 10.6
Glycated hemoglobin 5.0 ± 0.4 5.1 ± 0.4 ≤6.5 (%)
Total cholesterol 180 ± 18 175 ± 16 <200 (mg/dL)
HDL cholesterol 42 ± 9 49 ± 10 >35 (mg/dL)
LDL cholesterol 107 ± 15 117 ± 25 <160 (mg/dL)
Triglycerides 114 ± 31 115 ± 45 <160 (mg/dL)
17-beta estradiol 38 ± 5 28 ± 8 <60 (pg/mL)
Prolactin 12 ± 4 9 ± 5 2–17 (ng/mL)
Testosterone 5.1 ± 0.9 4.6 ± 2 3–10 (ng/mL)
LH 6.9 ± 2.9 5.7 ± 2.3 1.3–13 (U/L)
HDL: high-density lipoprotein; LDL: low-density lipoprotein; LH: luteinizing hormone.
Values are expressed as mean ± standard deviation (SD).
0.125mol/LNaCl, pH 10.75).The control incubationmixtures
(blanks) were set up using incubation mixtures without the
erythrocyte sample, which were incubated separately and
added immediately before stopping the reaction. To deter-
mine the activity ofO-GlcNAcase,which is only active toward
GlcNAc derivatives, the assay employed 4-MUB-N-acetyl-
𝛽-D-glucosaminide as substrate, in the presence of GalNAc
(50mmol/L) as a competitive inhibitor of hexosaminidase
A and hexosaminidase B [29]. Enzyme activities in plasma
membrane and cytosol are expressed as𝜇U/mgof protein and
mU/mL, respectively. Protein content was determined by the
method of Lowry et al. [30], using crystalline bovine serum
albumin as the standard.
2.5. Plasma Membrane Fluorescence Anisotropy. We assessed
the membrane fluidity of hydrocarbon core and of the region
of phospholipid head groups by measuring, respectively, the
steady-state anisotropy of DPH and TMA-DPH by Jasko FP-
770 spectrofluorimeter, following the method of Cazzola et
al. [31]. The DPH and TMA-DPH probes were excited at
a wavelength of 340 nm, and the emission wavelength was
set at 420 nm. Samples were then excited with vertically
polarized light andwemeasured the intensity of emitted light,
vertically (Iv) and horizontally (Ih) polarized with respect
to the exciting light. Anisotropy was calculated using the
equation 𝑟𝑠 = Iv− Ih/Iv+ 2Ih, where 𝑟𝑠 is inversely related to
membrane fluidity.
2.6. Evaluation of Plasma Peroxidation and Plasma Oxida-
tive Balance. Plasma lipid hydroperoxide levels (ROS) were
determined colorimetrically according to Trotti et al. [32] and
expressed as H
2
O
2
equivalents.
The kinetics of plasma oxidation, induced by addition of
0.5M CuSO
4
, were determined at 37∘C by monitoring the
development of fluorescence at 430 nm, setting the excitation
at 355 nm as described by Cervato et al. [33] by Multilabel
Counter Wallac 1420 from PerkinElmer. This method allows
the evaluation of the peroxidation kinetics monitored fol-
lowing the formation of fluorescent adducts originating from
the reaction of aldehydes (derived from lipid peroxidation
promoted by Cu++ bound to apolipoproteins) with amino
groups of plasma proteins and/or phospholipids. The kinetic
is expressed by a sigmoid curve that can be divided into an
initial latency phase, followed by a second propagation phase.
The initial latency phase (Lag-time, expressed in minutes
and calculated as the intercept of the linear regression of the
propagation phase with that of the latency phase) is an index
of lipoproteins resistance to peroxidation.
2.7. Statistical Analysis. Test of Kolmogorov-Smirnov showed
no significant differences from the normal distribution of
data. Therefore parametric techniques were used. Means
were compared by one-way analysis of variance (ANOVA).
All analyses were performed using the SPSS STATISTIC 22
package (SPSS Inc., Chicago, IL, USA).
3. Results
The clinical and metabolic parameters of the subjects in
study are reported in Table 1. All the parameters evaluated
fall within the reference ranges, both in controls and in ED
subjects.
Plasma hydroperoxide levels and plasma susceptibility
to peroxidation (Lag-time) are reported in Figure 1. As
expected, hydroperoxide levels of ED patients (mean ± SD:
27.6 ± 4.3; (range: 20.2–36.0)) are significantly (𝑃 < 0.001)
higher (+15%) than the control group (24.0±3.5; (19.2–29.7)).
The time lapse necessary to the total antioxidant defense
system of the plasma to inhibit the peroxidative process (Lag-
time) is significantly (𝑃 < 0.001) lower (−15%) in ED patients
(116 ± 16; (89–145)) than in the control group (135 ± 20; (110–
168)).
In Figure 2 the analyses of fluorescence anisotropy (𝑟𝑠) of
the erythrocyte membrane are reported. DPH probe shows
no significant differences between ED patients (0.185 ± 0.004;
(0.178–0.192)) and control group (0.187 ± 0.007; (0.171–
0.196)); a similar pattern is followed by TMA-DPH probe
with no significant differences between ED patients (0.231
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Figure 1: Plasma peroxidation parameters. Hydroperoxides are expressed as equivalent of H
2
O
2
mg/dL of plasma. ∗∗∗𝑃 < 0.001 controls
versus ED subjects.
± 0.004; (0.225–0.240)) and control group (0.234 ± 0.010;
(0.217–0.251)). Instead the enzymatic activities of membrane
bound glycohydrolases, Figure 2, are significantly higher in
ED than in controls: HEX 𝑃 < 0.01 (+27%) (ED patients:
58.1± 14.9; (27.9–93.1); control group: 45.7± 20.0; (19.8–71.2));
GCR 𝑃 < 0.01 (+22%) (ED patients: 539.3 ± 126.7; (315.8–
893.7); control group: 441.7 ± 175.1; (190.2–768.6)); and 𝛼-
GLU 𝑃 < 0.001 (+36%) (ED patients: 269.8 ± 71.2; (141.4–
424.4); control group: 198.3 ± 50.3; (109.7–317.8)).
Cytosolic HEX and O-GlcNAcase activities, showed in
Figure 3, are significantly lower in ED patients than in
controls: HEX 𝑃 < 0.001 (−39%) (ED patients: 31.3 ± 10.4;
(11.5–55.6); control group: 51.6 ± 26.8; (18.3–99.7)) and O-
GlcNAcase 𝑃 < 0.01 (−33%) (ED patients: 21.0 ± 6.8; (6.9–
37.9); control group: 31.0 ± 17.4; (11.7–59.9)).
4. Discussion
Recent studies have underlined the role of oxidative stress
in ED introducing the concept of penile neuropathy as
a free radical dependent oxidative stress injury [34]. It is
also well known that NO, derived from endothelial and
neuronal sources, plays an essential role in the early phases of
erection [3, 18, 35]. Therefore the interaction between nitric
oxide, synthesized by eNOS, and reactive oxygen species has
been proposed as one of the most important mechanisms
implicated in the pathophysiological process of the ED [36].
With regard to NO production a new view has been
provided by recent observations that a number of cytosolic
and nuclear proteins carry single residues of O-GlcNAc
and undergo functional modification depending on the
presence or removal of the amino sugar [17]. In particu-
lar, eNOS is activated by phosphorylation at Ser-1177, by
phosphatidylinositol-3-kinase/Akt/eNOS [37], and inacti-
vated by removal of phosphate and addiction of O-GlcNAc
residues at the same site by OGT [38]. By converse, removal
of O-GlcNAc residues, catalysed by O-GlcNAcase, allows the
phosphorylation of Ser-1177 and the activation of eNOS. It
has been demonstrated that human RBCs express an active
and functional endothelial-type eNOS, localized in both the
plasma membrane and the cytoplasm [19].
Moreover, there is a growing body of evidence that an
increased production of ROS leads to an increase in O-
GlcNAcylation levels [39]; consequently, it is reasonable to
hypothesize an emerging role of dysfunctional protein O-
GlcNAcylation/phosphorylation in ED.
Therefore, we decided to undertake a research in a group
of ED patients aimed to ascertain the possible relation
between membrane-bound and cytosolic glycohydrolases
content and praecox alterations due to oxidative stress.
To evaluate OS we used classical methodologies (plasma
hydroperoxide levels and membrane fluidity determination)
and measured antioxidant total defences by the Lag-time
method [33]. This analytical approach is useful as prognostic
index of plasmatic peroxidation risk in patientswith oxidative
pathologies (such as diabetes, cancer, hypertension, Down
syndrome, and chronic renal failure) [13, 40] and is an
efficient tool to monitor the effects of antioxidant treatments
[25].
Our findings suggest some interesting considerations.
First of all, both the evaluation of plasma hydroperoxides and
Lag-time (Figure 1) confirm previous observations showing
that the condition of oxidative stress in ED patients [26]
overlaps the well-known OS status in patients with other
pathologies [40]. Regarding peroxidation parameters, an
intriguing point is the observation that in ED subjects RBC
membrane fluidity shows no significant differences between
patients and controls (Figure 2).
Furthermore, the activities of the assayed glycohydrolases
in erythrocyte plasma membranes corroborate the evidence
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Figure 3: Glycohydrolases activities in the erythrocyte cytosol. ∗∗𝑃 < 0.01 and ∗∗∗𝑃 < 0.001 controls versus ED subjects.
resulting from plasma peroxidation parameters. Indeed, the
higher level of these membrane enzymes in ED patients
follows a very similar pattern already observed in Down syn-
drome patients [13], characterised by high level of oxidative
stress, and is opposite to the enzymatic pattern seen in
air force acrobatic pilots, known to be in an excellent
oxidative status [14]. This scenario, also considering the
similar levels of fluidity membrane between ED patients
and control subjects, may offer a further support of the
role of these membrane glycohydrolases in signaling early
membrane alterations before they become evident at a general
level across the membrane and detectable using fluorescent
probes, as showed in Figure 2.
Finally, the behavior of the two assayed glycohydrolases
in erythrocyte cytosol, Hexosaminidase and O-GlcNAcase,
undergoes a marked diminution in ED patients as compared
to controls (Figure 3). This pattern is quite similar to that
observed in Down syndrome patients [13] and opposite to
that seen in air force acrobatic pilots [14], and it stimulates
us to perform further investigations to study in depth
and clarify the relationship (that, to our knowledge, is yet
to be understood) between cytosolic HEX and oxidative
stress.
Of particular interest is the behaviour of O-GlcNAcase.
As already mentioned, O-GlcNAcylation plays a crucial role
in the complex signalling network involved in regulating
cellular responses to physiological and pathological stress
stimuli [41]. We can reasonably suppose that the observed
significant decrease of cytosolic O-GlcNAcase in ED patients
leads to a more persistent O-GlcNAcylation of eNOS Ser
1177 residue, hence enforcing the hypothesis of the crucial
involvement of RBC-NOS/eNOS in the mechanism of penile
erection.
5. Conclusions
Our data give further support to the role played by oxidative
stress in ED patients and emphasize the diagnostic potential
of the studied RBC glycohydrolases, as early biomarkers of
oxidative stress. Our data also provide an analytical support
to monitor the efficacy of antioxidant therapies aimed at
correcting oxidative stress [42].
Moreover, considering how, although indirectly, our data
suggest a scenario of increased glycosylations, additional
studies are also required to confirm and better define the role
played by erythrocyteO-GlcNAcase in the inhibition of RBC-
NOS activity and the subsequent failure to increase blood
flow in corpora cavernosa.
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